NCT06448273 - A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

TQB3702 tablets

TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.

DRUG

TQB3702 placebo

TQB3702 placebo contains no active substance.

Trial Locations (1)

RECRUITING

Guangdong provincial people's hospital, Guangzhou